Photocure Past Earnings Performance
Past criteria checks 3/6
Photocure's earnings have been declining at an average annual rate of -18.9%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 15.9% per year. Photocure's return on equity is 2.8%, and it has net margins of 2.7%.
Key information
-18.9%
Earnings growth rate
-19.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 15.9% |
| Return on equity | 2.8% |
| Net Margin | 2.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Photocure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 526 | 14 | 361 | 4 |
| 30 Jun 24 | 514 | 13 | 355 | 3 |
| 31 Mar 24 | 512 | 5 | 350 | 2 |
| 31 Dec 23 | 501 | 1 | 348 | 2 |
| 30 Sep 23 | 462 | -34 | 346 | 2 |
| 30 Jun 23 | 462 | -39 | 342 | 2 |
| 31 Mar 23 | 418 | -62 | 329 | 3 |
| 31 Dec 22 | 393 | -72 | 319 | 3 |
| 30 Sep 22 | 383 | -79 | 307 | 4 |
| 30 Jun 22 | 364 | -76 | 299 | 4 |
| 31 Mar 22 | 354 | -68 | 289 | 5 |
| 31 Dec 21 | 361 | -31 | 275 | 4 |
| 30 Sep 21 | 364 | 7 | 261 | 7 |
| 30 Jun 21 | 326 | 9 | 233 | 10 |
| 31 Mar 21 | 290 | 10 | 214 | 11 |
| 31 Dec 20 | 256 | -22 | 201 | 14 |
| 30 Sep 20 | 274 | 10 | 178 | 14 |
| 30 Jun 20 | 285 | 15 | 174 | 13 |
| 31 Mar 20 | 284 | 19 | 165 | 13 |
| 31 Dec 19 | 282 | 32 | 160 | 14 |
| 30 Sep 19 | 216 | -23 | 153 | 15 |
| 30 Jun 19 | 199 | -27 | 147 | 16 |
| 31 Mar 19 | 192 | -39 | 140 | 18 |
| 31 Dec 18 | 182 | -37 | 132 | 19 |
| 30 Sep 18 | 171 | -38 | 123 | 23 |
| 30 Jun 18 | 162 | -43 | 170 | 42 |
| 31 Mar 18 | 156 | -31 | 114 | 28 |
| 31 Dec 17 | 151 | -35 | 108 | 33 |
| 30 Sep 17 | 150 | -4 | 103 | 32 |
| 30 Jun 17 | 149 | 6 | 45 | 13 |
| 31 Mar 17 | 145 | 29 | 92 | 27 |
| 31 Dec 16 | 144 | 35 | 90 | 23 |
| 30 Sep 16 | 140 | 8 | 91 | 25 |
| 30 Jun 16 | 141 | 3 | 91 | 26 |
| 31 Mar 16 | 140 | -26 | 87 | 30 |
| 31 Dec 15 | 135 | -36 | 84 | 31 |
| 30 Sep 15 | 126 | -58 | 53 | 31 |
| 30 Jun 15 | 147 | -29 | 57 | 31 |
| 31 Mar 15 | 138 | -23 | 59 | 31 |
| 31 Dec 14 | 129 | -25 | 64 | 33 |
| 30 Sep 14 | 129 | -2 | 65 | 33 |
| 30 Jun 14 | 92 | -39 | 65 | 34 |
| 31 Mar 14 | 89 | -50 | 71 | 34 |
| 31 Dec 13 | 84 | -59 | 76 | 34 |
Quality Earnings: 0IMT has high quality earnings.
Growing Profit Margin: 0IMT became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0IMT has become profitable over the past 5 years, growing earnings by -18.9% per year.
Accelerating Growth: 0IMT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 0IMT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: 0IMT's Return on Equity (2.8%) is considered low.